Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RAR Gamma · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | po daily |
| RAR Gamma | EXPERIMENTAL | 5mg po daily |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | po daily |
| RAR Gamma | DRUG | 5mg po daily |
Inclusion Criteria: * patients of \>44 years of age, with \>10 pack-year smoking history; * women not of child-bearing potential; * ex-smokers (must have stopped smoking for \>=12 months) with clinical diagnosis of emphysema; * willing to be switched to optimal COPD therapy. Exclusion Criteria: *...
RAR Gamma is an investigational small molecule being studied for the treatment of emphysema, a form of chronic obstructive pulmonary disease. It is a gamma-selective retinoid agonist that was evaluated in a Phase 2 clinical trial. The drug is not approved and remains in clinical development.
RAR Gamma targets the retinoic acid receptor gamma, a nuclear receptor involved in cell growth and differentiation. As a gamma-selective retinoid agonist, it is designed to activate this specific receptor subtype. The drug was investigated for its potential to treat emphysema by promoting alveolar repair.
RAR Gamma is being developed by Roche Holding AG, a multinational healthcare company. Roche's stock is traded under the ticker RHHBY on the OTC market. The company conducted a Phase 2 clinical trial of RAR Gamma for emphysema.
RAR Gamma is in Phase 2 clinical development. It has completed one Phase 2 trial, which was a randomized, double-blind, placebo-controlled study. The drug is investigational and has not received FDA approval. Its development status is based on the completed Phase 2 trial.
RAR Gamma has one completed Phase 2 clinical trial, identified as NCT00413205, titled TESRA (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist). This trial enrolled 491 participants with emphysema across multiple countries, including the United States, Bulgaria, Czechia, Hungary, Iceland, Israel, Italy, Latvia, Poland, South Africa, Ukraine, and the United Kingdom.